

branded product for a period of 180 days.

Entry Into the Relevant Markets

Entry Into the markets for generic Femcon FE, Lo Loestrin 24 and its generic equivalents, Loestrin 24 FE and its generic equivalents, and Atelvia and its generic equivalents would not be timely, likely, or sufficient in magnitude, character, and scope to deter or counteract the anticompetitive effects of the acquisition. *De novo* entry would not take place in a timely manner because the combination of drug development times and FDA approval requirements would delay entry by at least two years. Even companies for which the FDA approval process is well underway face additional barriers, including Hatch-Waxman regulatory exclusivity and pending patent litigation, that prevent them from entering these markets in time to deter the price increases that would occur after consummation of the Proposed Acquisition.

The Anticompetitive Effects of the Acquisition

The Proposed Acquisition would cause significant anticompetitive harm to consumers in the U.S. markets for generic Femcon FE, Lo Loestrin 24 and its generic equivalents, Lo Loestrin FE and its generic equivalents, and Atelvia and its generic equivalents. The Proposed Acquisition would eliminate the current competition between the only two significant suppliers of generic Femcon FE, leading to significantly higher prices for this drug. The acquisition may also delay the onset of beneficial generic competition in the markets for Loestrin 24 FE, Lo Loestrin FE, and Atelvia. Evidence, including information regarding the status of the FDA approval process for potential suppliers of generic Loestrin 24 FE, suggests that Actavis will be the first generic supplier to compete against Warner Chilcott's branded product. Moreover, no other generic supplier is likely to enter the market for a significant period of time. Thus, the combined firm would likely delay the entry of Actavis's generic version of Loestrin 24 FE or, at a minimum, cause Actavis's generic drug to compete less vigorously against Warner Chilcott's branded product, resulting in higher prices for consumers. Similarly, in the markets for Lo Loestrin FE and Atelvia,

Actavis may be the first and only generic competitor to Warner Chilcott's branded products for a significant period absent the Proposed Acquisition. By eliminating this potential competition between Warner Chilcott and Actavis in each of these markets, the Proposed Acquisition would harm U.S. consumers by substantially increasing the likelihood of higher post-acquisition prices for Lo Loestrin FE and Atelvia.

The Proposed Consent Agreement

The proposed Consent Agreement effectively remedies the Proposed Acquisition's anticompetitive effects in the relevant markets by requiring Actavis to divest to Amneal certain rights and assets related to generic Femcon FE, generic Loestrin 24 FE, generic Lo Loestrin FE, and generic Atelvia no later than ten days after consummating the acquisition. In addition, the Consent Agreement requires Actavis to enter into a supply agreement to provide Amneal with generic versions of the Femcon FE and Loestrin 24 FE products to sell in the United States for up to four years. Amneal is a New Jersey-based generic pharmaceutical company that currently markets 65 products and maintains an active product development pipeline. With its experience in generic markets, Amneal is well positioned to replicate the competition that would otherwise be lost as a result of the Proposed Acquisition.

If the Commission determines that Amneal is not an acceptable acquirer of the assets to be divested, or that the manner of the divestitures is not acceptable, Actavis must unwind the sale to Amneal and divest the products within six months of the date the Order becomes final, to a Commission-approved acquirer. If Actavis fails to divest the products as required, the Commission may appoint a trustee to divest the products.

The proposed Consent Agreement contains several provisions to help ensure that the divestitures are successful. The Order requires Actavis to maintain the economic viability, marketability, and competitiveness of the divestiture products until such time as they are transferred to Amneal or another Commission-approved acquirer. Actavis must also transfer the manufacturing technology for the divestiture products to Amneal and

supply Amneal with the generic Femcon FE and Loestrin 24 FE products during the transition period. In addition, the Consent Agreement requires Actavis to relinquish any claim to marketing exclusivity for generic Lo Loestrin FE and Atelvia products to ensure that the incentives of the companies currently leading the patent litigations relating to those products do not change.

The purpose of this analysis is to facilitate public comment on the proposed Consent Agreement, and it is not intended to constitute an official interpretation of the proposed Order or to modify its terms in any way.

By direction of the Commission.

Donald S. Clark

Secretary.

[FR Doc. 2013-25847 Filed 10-30-13; 8:45 am]

BILLING CODE 6750-01-P

FEDERAL TRADE COMMISSION

Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination—on the dates indicated—of the waiting period provided by law and the premerger notification rules. The listing for each transaction includes the transaction number and the parties to the transaction. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

EARLY TERMINATIONS GRANTED
[September 1, 2013 thru September 30, 2013]

09/03/2013

20131084	G	Boston Scientific Corporation; C.R. Bard, Inc.; Boston Scientific Corporation.
20131136	G	Cisco Systems, Inc.; Sourcefire, Inc.; Cisco Systems, Inc.
20131205	G	David H. Murdock; Dole Food Company, Inc.; David H. Murdock.
20131211	G	Ronald O. Perelman; Beauty Care Professional Products Participations, S.A.; Ronald O. Perelman.
20131212	G	Rockwool International A/S; CMC Family Holdings LLC; Rockwool International A/S.

09/04/2013

20131227	G	Pianissimo Holdings Corp.; Steinway Musical Instruments, Inc.; Pianissimo Holdings Corp.
----------------	---	--

09/05/2013

20131180	G	Trian Partners Strategic Investment Fund, L.P.; E.I. du Pont de Nemours and Company; Trian Partners Strategic Investment Fund, L.P.
20131181	G	Trian Partners Strategic Investment Fund II, L.P.; E.I. du Pont de Nemours and Company; Trian Partners Strategic Investment Fund II, L.P.
20131187	G	CareGroup, Inc.; The Jordan Health Systems, Inc.; CareGroup, Inc.
20131223	G	Parametric Sound Corporation; VTB Holdings, Inc.; Parametric Sound Corporation.

09/09/2013

20131225	G	Jeffrey P. Bezos; The Washington Post Company; Jeffrey P. Bezos.
20131226	G	Crestview Partners II (Outbound), L.P.; Sterling Group Partners III (AIV), L.P.; Crestview Partners II (Outbound), L.P.
20131229	G	Allied Motion Technologies Inc.; Safran SA; Allied Motion Technologies Inc.
20131234	G	Crystal T, LLC; Onex Partners II LP; Crystal T, LLC.
20131240	G	ONEOK Partners, L.P.; Merit Energy Company, LLC; ONEOK Partners, L.P.
20131243	G	CH Holding L.P.; Bend Research, Inc.; CH Holding L.P.

09/10/2013

20131238	G	Francisco Partners III, L.P.; Austin Ventures VIII, L.P.; Francisco Partners III, L.P.
20131242	G	Atlas Copco AB; Edwards Group Limited; Atlas Copco AB.

09/11/2013

20131192	G	Actelion Ltd.; Ceptris Therapeutics, Inc.; Actelion Ltd.
20131246	G	loanDepot.com, LLC; imortgage.com, Inc.; loanDepot.com, LLC.

09/12/2013

20131197	G	Perrigo Company; Elan Corporation, plc; Perrigo Company.
20131198	G	Elan Corporation plc; Perrigo Company; Elan Corporation plc.
20131228	G	KKR European Fund III, Limited Partnership; RigNet, Inc.; KKR European Fund III, Limited Partnership.
20131247	G	Nabors Industries Ltd.; Richard W. Wurster; Nabors Industries Ltd.
20131248	G	Nabors Industries Ltd.; Danny R. Shaffer; Nabors Industries Ltd.

09/13/2013

20130504	G	Honeywell International Inc.; Intermed, Inc.; Honeywell International Inc.
20131206	G	C.R. Bard, Inc.; Medafor, Inc.; C.R. Bard, Inc.
20131267	G	John S. Chiorando; Personal Communications Devices Holdings LLC; John S. Chiorando.

09/16/2013

20131224	G	Partners Limited; Entergy Corporation; Partners Limited.
20131262	G	Sterling Group Partners III, L.P.; Century Park Capital Partners II, L.P.; Sterling Group Partners III, L.P.

09/18/2013

20131263	G	Amgen Inc.; Onyx Pharmaceuticals, Inc.; Amgen Inc.
----------------	---	--

09/19/2013

20131254	G	The Madison Square Garden Company; Azoff MSG Entertainment LLC; The Madison Square Garden Company.
----------------	---	--

09/20/2013

20131273	G	Providence Equity Partners VII-A L.P.; Shamrock Capital Growth Fund III, L.P.; Providence Equity Partners VII-A L.P.
20131276	G	MDCP VI-A Global Investments LP; Madison Dearborn Capital Partners VI-A, L.P.; MDCP VI-A Global Investments LP.
20131284	G	2349468 Ontario Limited; Ryan A. Busbice; 2349468 Ontario Limited.
20131285	G	Morgan McCague; Ryan A. Busbice; Morgan McCague.

EARLY TERMINATIONS GRANTED—Continued

[September 1, 2013 thru September 30, 2013]

20131287	G	Centerbridge Capital Partners II (Cayman), L.P.; GenNx360 Capital Partners, L.P.; Centerbridge Capital Partners II (Cayman), L.P.
20131288	G	Magellan Health Services, Inc.; Mark V. Mertel and Miriam Mertel; Magellan Health Services, Inc.

09/23/2013

20131217	G	Verizon Communications Inc.; Telephone and Data Systems, Inc. Voting Trust; Verizon Communications Inc.
----------------	---	---

09/24/2013

20131244	G	Arrow Electronics, Inc.; CSS Computer Security Solutions Holding GmbH; Arrow Electronics, Inc.
20131259	G	AstraZeneca PLC; Amplimmune, Inc.; AstraZeneca PLC.
20131271	G	Cisco Systems, Inc.; Whiptail Technologies, Inc.; Cisco Systems, Inc.
20131279	G	Calfrac Well Services Ltd.; Mission Investment Partners, LLC; Calfrac Well Services Ltd.
20131281	G	Oasis Petroleum Inc.; Dawn Arnall; Oasis Petroleum Inc.
20131291	G	Heico Corporation; Lucix Corporation; Heico Corporation.
20131295	G	NM Mariposa Holdings, Inc.; Newton Holding, LLC; NM Mariposa Holdings, Inc.

09/25/2013

20131253	G	Capital One Financial Corporation; Beech Street Capital Holdings, LLC; Capital One Financial.
20131280	G	Corporation VEPF IV AIV VI, L.P.; QUALCOMM Incorporated; VEPF IV AIV VI, L.P.

09/27/2013

20130759	G	Mylan Inc.; Strides Arcolab Limited; Mylan Inc.
20130959	S	Actavis, Inc.; Warner Chilcott plc; Actavis, Inc.
20130960	S	Warner Chilcott plc; Actavis, Inc.; Warner Chilcott plc.
20131255	G	FR XII Charlie AIV, L.P.; Utility Services Associates, Inc.; FR XII Charlie AIV, L.P.
20131275	G	LS Power Equity Partners II, L.P.; FirstEnergy Corp.; LS Power Equity Partners II, L.P.
20131299	G	Koch Industries, Inc.; Molex Incorporated; Koch Industries, Inc.
20131306	G	The Resolute Fund II, L.P.; Harbour Group Investments V, L.P.; The Resolute Fund II, L.P.
20131307	G	Anthony C. and Alice C. Cibilih; The Resolute Fund II Maritime Partnership, L.P.; Anthony C. and Alice C. Cibilih.
20131308	G	Twitter, Inc.; MoPub Inc.; Twitter, Inc.
20131309	G	Aurora Resurgence Fund II L.P.; Aurora Resurgence Fund (C) L.P.; Aurora Resurgence Fund II L.P.
20131318	G	Clayton, Dubilier & Rice Fund IX, L.P.; FR XI Offshore AIV, L.P.; Clayton, Dubilier & Rice Fund IX, L.P.

09/30/2013

20131174	G	Centrica plc; Hess Corporation; Centrica plc.
20131264	G	University of Maryland Medical System, Corp.; Upper Chesapeake Health System, Inc.; University of Maryland Medical System, Corp.
20131268	G	Third Point Ultra, Ltd.; Sotheby's; Third Point Ultra, Ltd.
20131269	G	Third Point Offshore Fund, Ltd.; Sotheby's; Third Point Offshore Fund, Ltd.
20131301	G	The Resolute Fund II Maritime Partnership, L.P.; Abdon Callais Offshore, LLC; The Resolute Fund II Maritime Partnership, L.P.
20131303	G	EnerSys; Purcell Systems, Inc.; EnerSys.
20131343	G	Packaging Corporation of America; Boise Inc.; Packaging Corporation of America.

FOR FURTHER INFORMATION CONTACT:

Renee Chapman, Contact Representative, or Theresa Kingsberry Legal, Assistant. Federal Trade Commission Premerger, Notification Office Bureau of Competition, Room H-303, Washington, DC 20580, (202) 326-3100.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 2013-25710 Filed 10-30-13; 8:45 am]

BILLING CODE 6750-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Committee on Vital and Health Statistics: Meeting Standards Subcommittee

Pursuant to the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) announces the following advisory committee meeting.

Name: National Committee on Vital and Health Statistics (NCVHS) Subcommittee on Standards.

Time and Date: November 12, 2013 8:30 a.m.–5:30 p.m. EST.

Place: Centers for Disease Control and Prevention, National Center for Health Statistics, 3311 Toledo Road, Auditorium B

& C, Hyattsville, Maryland 20782, (301) 458-4524.

Status: Open.

Purpose: The purpose of this hearing is to gather industry input on the state of health data standards used by public health and population health programs, and the scope of the meeting will include standards used for electronic exchange of information between public health and external stakeholders. This includes standards for data coding, document-type standards, message content, structure and format standards, transport, vocabulary and terminology, and data management standards across various public health functions and activities including but not limited to vital statistics, bio-surveillance, syndromic surveillance, screening, immunizations, public health laboratory, environmental health, and public health/population health analytics. Coding and classification systems for certain core public health data elements will be included.